Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

Author(s): Nageshwar Budha, Maya Leabman, Jin Jin, Russell Wada, Amos Baruch, Kun Peng, Whittemore Tingley, John Davis
Year: March 31, 2015
Learn More LinkedIn Twitter Facebook Email